underli result solid top in-line
ep adjust cynosur inorgan factor top
bottom line guidanc rais consist
expect see top end guidanc
like
solid result consist pre-announc report
revenu organ ex cynosur impli bp momentum
acceler see pre-announc line top end
guidanc beat vs consensu rel in-lin adjust
ssi blood breast revenu in-lin grew
organ bp momentum deceler challeng
comparison strong us gantri quarter dx growth acceler
bp momentum basi driven continu strength molecular surgic
revenu beat estim acceler bp momentum
basi surpris given new product launch traction see
outlook cynosur revenu light estim perhap
driven disrupt result divestitur announc move
forward includ result therefor expect
focu quarter
guidanc ex cynosur rais
overli surpris given note typic guid conserv
rais throughout year see take midpoint guidanc
organ guidanc impli absolut acceler
stabil momentum basi model remain rel unchang
model organ growth ex cynosur may prove
conserv term segment driver still expect key breast dx
franchis slow margin y/i mainli due challeng comp said
guidanc emb acceler see driven new product
uptak surgic continu assay traction molecular brevera
headwind eas becom tailwind
reconcil ep guidanc consist preview rais ep
medic technolog unit state america
unless otherwis note metric base modelwar
consensu data provid thomson reuter estim
seek busi
compani cover morgan stanley research
result investor awar firm may
conflict interest could affect object
morgan stanley research investor consid
morgan stanley research singl factor make
invest decis
analyst certif import disclosur
refer disclosur section locat end
guidanc midpoint recal
initi manag forecast cynosur asr accret
ep see howev segment miss drove ep net see
updat bridg follow cynosure/asr net-neutr
state intent increas invest spend base bridg
see materi chang plan margin math conclud
impli margin guidanc bp y/i key point
margin accret analysi see conclud manag
bp commentari conserv cynosur accret key
investor focu item sinc announc drive share out-performance
light top-line segment miss see cynosur drive materi
ep accret updat guidanc forecast addit share
repurchas outsid asr conclud despit
author begin see potenti pocket conservat
note repurchas drive ep sever pocket
conservat continu see ep guidanc conserv
comfort model guidanc y/i
setup cleaner sinc cynosur sale announc see
share outperform market point remov
persist overhang taken posit investor continu expect
upsid throughout via top-line beat/rais see limit room
multipl expans compani wamgr remain structur
peer oper leverag beyond cynosur accret limit
om/gm ratio vs peer expect tuck-in activ continu
commentari clear compani deal
scale updat price target reflect increas peer
multipl valuat methodolog base ebitda
discount larg cap peer
price target base ebitda multipl
turn discount larg cap devic peer see discount
warrant given oper slower growth end-market
limit top-line upsid effici structur limit ep
upsid beyond hsd/ldd growth partli driven buy-back activ
breast health diagnost segment acceler drive organ
growth effici alloc capit accret shift
wamgr msd region creat sustain runway
growth cynosur drive materi ep accret augment share
breast health diagnost segment modestli deceler
surgic acceler via new product launch continu myosur
momentum activ necessari fundament shift growth profil
higher leverag limit near-term given current margin structur
suggest effici share buyback continu drive es growth
busi organ growth deceler back region share
gain becom tap breast dx ep growth mute msd driven
limit oper leverag buy-back activ ineffici capit
deploy creat dis-synergi advers impact organ growth
share gain key segment breast dx
nearli tap
compani alreadi oper
effici om/gm ratio vs peer
leverag ep growth like
deriv buyback
see increas activ necessari
shift wagmr higher drive
digit mammographi
system market yet convert
creat ampl runway breast health
cynosur divestitur drive
bp oper margin
and/or share repurchas buy-back
activ drive point ep growth
competit commerci surgic
risk achiev price
deploy capit enter faster
growth end market drive ep growth
greater expect share
breast health dx segment growth
rate acceler
novasur manag competit
threat maintain share
million except ep
sale
sale
sale
sale
good sold
invest
treasuri
accumul comprehens
loss dispos properti equip
excess tax benefit relat equiti award
charg in-process d/writeoff
net chang work capit
purchas properti equip
dispos properti equip
busi acquisit net cash
net cash paid acquisit intang
proce sale intellectu properti
chg short-term debt
chg long-term debt
chang equiti net tax benefit
net decreas invest
tax benefit exercis non-qual option
effect exchang rate chang
begin period
end period
